These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 2120016)

  • 21. [Clinical application of DDVP on hemophiliacs].
    Kobayashi I; Takahashi H
    Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):975-86. PubMed ID: 6818810
    [No Abstract]   [Full Text] [Related]  

  • 22. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A.
    Rodeghiero F; Castaman G; Mannucci PM
    Thromb Haemost; 1996 Nov; 76(5):692-6. PubMed ID: 8950775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immune coagulation disorders (excluding antiphospholipid syndrome].
    Arai M
    Rinsho Byori; 2001 Oct; 49(10):1000-4. PubMed ID: 11769464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factor VIII competitive enzyme assay: observations in von Willebrand's variants and hemophiliacs.
    Yorde LD; Yorde DE; Sasse EA; Hussey CV
    Clin Physiol Biochem; 1984; 2(6):298-303. PubMed ID: 6440727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease.
    Josephson CD; Abshire TC
    Best Pract Res Clin Haematol; 2006; 19(1):35-49. PubMed ID: 16377540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The treatment of inherited coagulation disorders].
    Blombäck M; Nilsson IM
    Lakartidningen; 1972 Dec; 69():Suppl 4:76-84. PubMed ID: 4540328
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetics of VWF/FVIII concentrates is a very intricate matter.
    Morfini M
    Haemophilia; 2011 Nov; 17(6):846-8. PubMed ID: 22029760
    [No Abstract]   [Full Text] [Related]  

  • 29. Acquired haemophilia in association with type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa.
    Majumdar G; Phillips JK; Lavallee H; Savidge GF
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1035-7. PubMed ID: 8148477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pioneering designs for recombinant coagulation factors.
    Schulte S
    Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The spectrum of von Willebrand's disease revisited.
    Bowie EJ; Fass DN; Olson JD; Owen CA
    Mayo Clin Proc; 1976 Jan; 51(1):35-41. PubMed ID: 765637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in the detection of carriers of haemophilia A, B and Von Willebrand's disease.
    Schinco PM; Rizza CR
    Haematologica; 1983; 68(1):124-34. PubMed ID: 6404703
    [No Abstract]   [Full Text] [Related]  

  • 33. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
    Jacquemin M
    Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.
    Owaidah T; Momen AA; Alzahrani H; Almusa A; Alkasim F; Tarawah A; Nouno RA; Batniji FA; Alothman F; Alomari A; Abu-Herbish S; Abu-Riash M; Siddiqui K; Ahmed M; Mohamed SY; Saleh M
    Medicine (Baltimore); 2017 Jan; 96(2):e5456. PubMed ID: 28079788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
    Berntorp E
    Semin Thromb Hemost; 2006 Sep; 32(6):621-5. PubMed ID: 16977572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood and neoplastic diseases. Haemophilia and related disorders.
    Rizza CR
    Br Med J; 1974 Oct; 4(5935):36-8. PubMed ID: 4547674
    [No Abstract]   [Full Text] [Related]  

  • 37. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug therapy reviews: clinical use of hemostatic agents.
    Lowe GD; Lawson DH
    Am J Hosp Pharm; 1978 Apr; 35(4):414-22. PubMed ID: 306196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Children's preferences of transfer devices for reconstitution of factors VIII and IX for the treatment of haemophilia.
    Khair K
    Haemophilia; 2009 Jan; 15(1):159-67. PubMed ID: 19016902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical aspects of hemophilia and von Willebrand's disease.
    Ciavarella D; Counts RB
    Am J Med Technol; 1983 Dec; 49(12):850-4. PubMed ID: 6422754
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.